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BACKGROUND AND PURPOSE
6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) is an essential cofactor for nitric oxide biosynthesis. Substantial clinical evidence
indicates that intravenous BH4 restores vascular function in patients. Unfortunately, oral BH4 has limited efficacy. Therefore,
orally bioavailable pharmacological activators of endogenous BH4 biosynthesis hold significant therapeutic potential.
GTP-cyclohydrolase 1 (GCH1), the rate limiting enzyme in BH4 synthesis, forms a protein complex with GCH1 feedback
regulatory protein (GFRP). This complex is subject to allosteric feed-forward activation by L-phenylalanine (L-phe). We
investigated the effects of L-phe on the biophysical interactions of GCH1 and GFRP and its potential to alter BH4 levels in vivo.
EXPERIMENTAL APPROACH
Detailed characterization of GCH1–GFRP protein–protein interactions were performed using surface plasmon resonance (SPR)
with or without L-phe. Effects on systemic and vascular BH4 biosynthesis in vivo were investigated following L-phe treatment
(100 mg·kg−1, p.o.).
KEY RESULTS
GCH1 and GFRP proteins interacted in the absence of known ligands or substrate but the presence of L-phe doubled maximal
binding and enhanced binding affinity eightfold. Furthermore, the complex displayed very slow association and dissociation
rates. In vivo, L-phe challenge induced a sustained elevation of aortic BH4, an effect absent in GCH1(fl/fl)-Tie2Cre mice.
CONCLUSIONS AND IMPLICATIONS
Biophysical data indicate that GCH1 and GFRP are constitutively bound. In vivo, data demonstrated that L-phe elevated
vascular BH4 in an endothelial GCH1 dependent manner. Pharmacological agents which mimic the allosteric effects of L-phe
on the GCH1–GFRP complex have the potential to elevate endothelial BH4 biosynthesis for numerous cardiovascular disorders.
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BH4, 6R-L-erythro-5,6,7,8-tetrahydrobiopterin; Bmax, maximal binding; F-GCH1, native/full length GCH1; GCH1, GTP
cyclohydrolase 1; GFRP, GCH1 feedback regulatory protein; KD, equilibrium dissociation constant; koff, dissociation rate
constant; kon, association rate constant; L-phe, L-phenylalanine; NOS, nitric oxide synthase; PKU, phenylketonurea; SPR,
surface plasmon resonance; T-GCH1, truncated GCH1
Introduction
GTP-cyclohydrolase 1 (GCH1) catalyses the committing and
rate limiting step in the production of 6R-L-erythro-5,6,7,8-
tetrahydrobiopterin (BH4), an essential cofactor for aromatic
amino acid hydroxylases (Kaufman, 1963), nitric oxide syn-
thase (NOS) (Tayeh and Marletta, 1989) and alkylglycerol
mono-oxygenase (Watschinger et al., 2010). The products of
these enzymes have widespread functions (Thöny et al.,
2000) and hence GCH1, via its control of BH4 biosynthesis,
regulates a number of diverse physiological systems.
Numerous clinical studies have shown that intravascular
BH4 administration, at high concentrations, significantly
improves endothelial function in patients with a wide range
of cardiovascular disorders, by increasing nitric oxide (NO)
bioavailability and/or reducing oxidative stress (Heitzer et al.,
2000; Higashi et al., 2002; Wyss et al., 2005; Mayahi et al.,
2007). Unfortunately, BH4 is very unstable and, when orally
administered, has limited efficacy likely due to oxidation
during absorption (Cunnington et al., 2012). Therefore, other
approaches to directly raise endogenous BH4 biosynthesis
hold therapeutic potential – one such approach involves the
pharmacological activation of GCH1, within the vascular
endothelial cells themselves.
Interestingly, mammals have evolved an endogenous
system to dynamically regulate GCH1 activity, whereby the
enzyme’s activity can be inhibited by BH4 (via end product
feedback inhibition), or activated by L-phenylalanine
(L-phe). However, this dynamic post-translational regulation
only occurs when GCH1 is bound to GCH1 feedback regula-
tory protein (GFRP) (Harada et al., 1993). In vitro studies have
demonstrated that when GCH1 and GFRP are bound, BH4
mediates allosteric feedback inhibition of GCH1, in a non-
competitive manner, whilst L-phe can reverse this effect –
stimulating GCH1 activity (Harada et al., 1993; Maita et al.,
2004). Importantly, this allosteric regulation of GCH1 activity
has an absolute requirement for GFRP, as BH4 and L-phe are
unable to influence the activity of purified GCH1 protein in
isolation (Harada et al., 1993).
These feedback and feed-forward mechanisms ensure that
BH4 is kept within a tight physiological range in the body. As
BH4 is an essential cofactor for the metabolism of dietary
L-phe by phenylalanine hydroxylase, the L-phe mediated
feed-forward activation of GCH1 raises endogenous BH4 and
ensures that dietary L-phe is adequately metabolized. This is
clinically important as L-phe can be neurotoxic above a
certain concentration, leading to irreversible mental disabil-
ity. Indeed, BH4 supplementation is currently used to treat a
subset of L-phenylketonuria (PKU) patients who are unable to
metabolize L-phe (Heintz et al., 2013). The differential effi-
cacy of oral BH4 supplementation between coronary artery
disease patents and those with PKU may be explained by the
presence of enhanced oxidative stress, which subsequently
leads to oxidative inactivation of BH4 during absorption in
the former, but not the latter, patient group (Cunnington
et al., 2012).
The presence of a functional GCH1–GFRP complex has
been demonstrated in humans, whereby oral administration
of L-phe elicits an increase in plasma biopterin (a surrogate
marker of BH4) – an effect that is attenuated in patients
carrying a loss of function GCH1 mutation (Saunders-
Pullman et al., 2004). However, the effects of L-phe on biop-
terin and, more importantly, BH4 levels in tissues have not
been directly determined.
The crystal structure of the GCH1–GFRP complex has
been solved, revealing GCH1 as a homodecamer (∼280 kDa)
sandwiched between two GFRP homopentamers (∼50 kDa).
These crystal structures revealed discrete binding pockets for
L-phe and BH4 located at the GCH1–GFRP interface and dis-
tinct from the GTP binding site (Maita et al., 2002; 2004),
making these unique and rational drug targets to either
enhance or limit BH4 biosynthesis respectively. Upon binding
to their respective pockets at the GCH1–GFRP interface, BH4
and L-phe induce conformational changes in the remote GTP
substrate binding pocket, impeding or facilitating GTP
binding respectively (Maita et al., 2002; 2004). However, to
date, crystallization studies have been limited to a truncated
form of mammalian GCH1, lacking the first 42 amino acids
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due to N-terminal instability (Auerbach et al., 2000; Maita
et al., 2002; 2004). Whilst these studies stated that this
N-terminal region did not influence GFRP binding, feedback
regulation or GCH1 activity, other studies have contradicted
these findings, suggesting that the absence of a complete
N-terminal region can alter GCH1 activity and further limits
the capacity of GCH1 to bind to GFRP (Swick and Kapatos,
2006; Higgins and Gross, 2011).
We hypothesized that drugs which mimic the allosteric
effects of L-phe on the GCH1–GFRP complex have the poten-
tial to elevate BH4 within vascular cells and restore endothe-
lial function in numerous cardiovascular disorders,
circumventing the limitations of oral BH4 treatment.
However, to facilitate a rational drug discovery approach, a
greater understanding of the GCH1 : GFRP complex and the
potential limitations of the current crystal structures (which
used an N-terminal truncation mutant) is required. Further-
more, in vitro and in vivo proof of concept studies validating
the GCH1–GFRP axis as a tangible drug target to regulate
endothelial BH4 are also lacking.
Therefore, in this study, we have quantified GCH1–GFRP
protein interactions using surface plasmon resonance (SPR),
comparing native/full length (F-GCH1) and truncated GCH1
(T-GCH1) binding to GFRP. Additional studies evaluated the
impact of L-phe on GCH1–GFRP interactions. Furthermore,
whilst L-phe is known to raise plasma biopterin in human
plasma, little is known of the impact of GCH1-GFRP stimu-
lation in vascular cells and tissues. We therefore undertook
in vitro studies establishing the effects of L-phe administration
on BH4, nitric oxide levels and superoxide anion levels,
in cultured endothelial cells. Furthermore, we investigated
the in vivo impact of oral L-phe challenge on aortic and
systemic biopterin and BH4 levels in both wild-type mice and
in mice lacking endothelial GCH1 [GCH1(fl/fl)-Tie2Cre]
(Chuaiphichai et al., 2014).
Methods
Cloning and construct formation
Human liver mRNA (AMS Biotechnology UK Ltd: M1234149)
was reverse transcribed using the GE Healthcare First Strand
cDNA Synthesis Kit. DNA encoding native GFRP, F-GCH1 and
T-GCH1 (lacking the first 42 N-terminal amino acids) was
amplified from the cDNA by PCR using KOD hot start poly-
merase (VWR International, Lutterworth, UK). PCR products
(GFRP, F-GCH1 and T-GCH1) were individually purified,
digested and ligated into the dual expression vector pDuet-1
encoding an N-terminal His6-tag in MCS1, using appropriate
restriction enzymes. MCS2 was used for co-expression of non-
tagged proteins. All PCR primers encoded a TEV cleavage site
for removal of the His6 tag after protein purification (Table 1).
Competent Escherichia coli strains BL21 (DE3) and Rosetta
were transformed with ligation mixtures. DNA sequencing
authenticated the clones.
Protein expression and purification
Overnight bacterial cultures were induced using 1 mM iso-
propyl β-D-1-thiogalactopyranoside at 25°C for 12 h. His6-
tagged proteins, either alone or bound to non-tagged
co-expressed proteins, were purified using Talon cell-thru
metal affinity resin (Takara-Bio Europe/Clontech, Saint-
Germain-En-Laye, France). For SPR experiments, purified pro-
Table 1
Construct details
Construct
Vector and multiple
cloning site
Restriction enzyme
± TEV site Primers (5′–3′)
T-GCH1 (FWD) pET-Duet MCS 1 Sal1-TEV GATCGTCGACGAAAACCTGTACTTCCA
AGGAGAGGCCAAGAGCGCGCAGCCC
T-GCH1 (REV) pET-Duet MCS 1 Not1 CTGATAGCGGCCGCTCAGCTCCTAATGA
GCGTCAGGAA
F-GCH1 (FWD) pET-Duet MCS 1 Sal 1-TEV GATCGTCGACGAAAACCTGTACTTCCA
AGAAATGGAGAGAAGGGCCCTGTGCG
GGCACCGGCGGAG
F-GCH1 (RVS) pET-Duet MCS 1 Not1 CTGATAGCGGCCGCTCAGCTCCTAATGA
GCGTCAGGAA
GFRP (FWD) pET-Duet MCS 1 Sal1-TEV GATCGTCGACGAAAACCTGTACTTCCA
AGGACCCTACCTGCTCATCAGCACCCA
GATC
GFRP (RVS) pET-Duet MCS 1 Not1 CTGATAGCGGCCGCTCACTCCTTGTGCA
GACACCACACCAGCGTCTG
GFRP (FWD) pET-Duet MCS 2 Fse1 CTGATA GGCCGGCC CCC TAC CTG CTC ATC AGC ACC CAG ATC
GFRP (RVS) pET-Duet MCS 2 Kpn1 GATC GGTACC TCA CTC CTT GTG CAG ACA CCA CAC CAG CGT CTG
Each construct was generated by PCR amplification with corresponding oligonucleotide primers, as listed. A TEV site was incorporated for
removal of the His6 tag. T-GCH1 (truncated mutant lacking the first N-terminal 42 amino acids).
F-GCH1, native/full length GCH1; GFRP, GCH1 feedback regulatory protein; T-GCH1, truncated GCH1.
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teins were incubated with TEV protease at 30°C overnight to
cleave the His-tag, and then co-incubated with the affinity
resin (4 h) to remove the cleaved His-tag. Finally, protein
samples were run through a size exclusion chromatography
Superdex column (GE Healthcare Ltd, Buckinghamshire, UK).
Proteins were identified by SDS-PAGE and Western blot-
ting using either a polyclonal primary GCH1 anti-peptide
antibody (raised against amino acid residues 18–45) (Nandi
et al., 2005), a commercial primary GFRP antibody (Santa
Cruz Biotechnologies, Santa Cruz, CA) or a His-tag antibody
(Abcam, Cambridgeshire, UK). Purified protein samples were
combined and concentrated in 100 mM Tris pH 7.8, 100 mM
NaCl or 50 mM HEPES pH 7.8, 100 mM KCl.
GCH1 activity (HPLC). GCH1 activity was assessed by HPLC
as previously described (Howells et al., 1986), whereby neop-
terin content was quantified by isocratic HPLC and fluores-
cence detection. Quantification of neopterin was carried out
by comparison with external standards and was normalized
for sample protein content.
GCH1 activity kinetic microplate assay. An established kinetic
microplate assay was modified and used to measure GCH1
activity in expressed proteins, in addition to HPLC (Kolinsky
and Gross, 2004). This assay measures the accumulation of
the intermediate reaction product, dihydroneopterin triphos-
phate (H2NTP), by monitoring an increase in A340 over time.
The assay was set up in a 96-well plate format as follows:
0.25 μM GCH1 protein (T or F) was combined with assay
buffer (100 mM Tris–HCl to a final volume of 300 μL) and
100 μM GTP (Thermo Fisher Scientific, Hemel Hempstead,
UK). Purified GFRP protein (1 μM) was added in certain
experiments. Absorbance (340 nm) was measured using a
Spectramax temperature controlled plate reader (Molecular
Devices Ltd, Wokingham, UK) at 37°C until the reaction
reached saturation. Absorbance units were expressed in mol
H2NTP as previously described (Kolinsky and Gross, 2004).
SPR
A Biacore™ T200 was used to conduct SPR experiments.
F-GCH1, T-GCH1 or GFRP proteins obtained from single
expression vectors were captured on a CM5 sensor chip
surface using an anti-His-tag antibody (Biacore His-capture
Kit; GE Healthcare Ltd). The sensor chip was activated using a
1:1 mixture of 50 mM N-hydroxysuccinimide and 200 mM of
N-ethyl-N′-(diethylaminopropyl) carbodiimide. This was
injected across two flow cells simultaneously, with the second
flow cell acting as a control surface to identify any non-
specific binding. A 50 μg·mL−1 anti-His-tag antibody solution
was injected over the experimental flow cell and both experi-
mental and control surfaces were subsequently quenched
with 1 M ethanolamine HCl (pH 8.5). His-tagged protein
(100 nM) in running buffer (50 mM HEPES pH 7.4, 150 mM
NaCl, 3 mM EDTA, and 0.005% (v/v) surfactant P20) was
injected across both flow cells, allowing the protein to be
captured by the anti-His-tag antibody immobilized on the
surface of the experimental flow cell. Experiments were per-
formed with F-GCH1 or T-GCH1 captured on a CM5 surface
(with GFRP as the analyte), and reciprocally with GFRP cap-
tured on the surface (with either T-GCH1 or F-GCH1 as the
analyte). For the analyte proteins, the His-tag was cleaved and
the protein incorporated into the running buffer over a range
of concentrations (100–2000 nM). Analyte proteins were
injected across both flow cells. The surface was regenerated
using an injection of 10 mM glycine (pH 1.5) following each
analyte cycle. In separate experiments, L-phe (100 μM) or BH4
(20 μM) was introduced along with the analyte protein into
the running buffer. Flow rates were adjusted accordingly to
enable equilibration (flow rate of 3 μL·min−1 for 7000 s). All
SPR assays were conducted at 25°C. Surface density after
ligand immobilization was maintained at 1250–1500 RU for
all experiments. Dose-dependent association experiments
and binding characterization experiments were repeated four
times.
In vitro and vivo studies
Animal welfare and ethical statement. All animals studies
described in this paper were conducted following ethics
approval and in accordance with the UK Home Office Animals
(Scientific Procedures) Act 1986 [Amendment Regulations (SI
2012/3039)]. Experimental design and conduct were under-
taken in accord with the ARRIVE guidelines (Kilkenny et al.,
2010) and complied with The Basel Declaration and the Con-
cordat on Openness on Animal Research. All techniques used
for in vivo studies were as humane as possible. A total of 80
animals were used in the experiments described here.
L-phe challenge in wild-type and GCH1(fl/fl)-Tie2Cre
mice. Three groups of mice were used for in vivo studies: (i)
male C57BL/6 mice (12–14 weeks old), purchased from a
commercial supplier (Harlan Laboratories, Loughborough,
UK); (ii) GCH1(fl/fl)-Tie2Cre (KO) mice and (iii) GCH1(fl/fl)
mice – hereafter referred to as wild-type littermates – gener-
ated by crossing male GCH1(fl/fl)-Tie2cre and female
GCH1(fl/fl) mice (Chuaiphichai et al., 2014). All animals were
group housed with 12 h light/dark cycle and controlled tem-
perature of 20–22°C and given access to a standard chow diet
and water ad libitum. GCH1(fl/fl)-Tie2Cre mice have previ-
ously been shown to lack GCH1 in endothelial cells
(Chuaiphichai et al., 2014).
L-phe (100 mg·kg−1) in saline was administered orally (by
gavage) to all three groups of mice. This dose is equivalent to
∼200 g of beef in a healthy 70 kg adult (Uhe et al., 1997) and
matches the dose used in L-phe loading studies in PKU
patients (Saunders-Pullman et al., 2004). Mice were killed, by
exsangination under isoflourane anaesthesia, after 20 min, 1,
2, 4 or 8 h. Plasma and aortic tissues were collected and snap
frozen for subsequent analysis of L-phe, biopterin and BH4
levels. L-phe levels were measured using HPLC detection in
plasma and tissue homogenates following sample prepara-
tion as described previously (Atherton and Green, 1988).
Quantification of L-phe was performed by comparison with
external standards (0–250 mmol·L−1) and the lower limit of
detection was 2.7 μM. Values were normalized for protein
content using a standard Bradford assay.
L-phe challenge in sEnd1 endothelial cells. sEnd-1 cells (a
stable murine endothelial cell line) were cultured in DMEM as
previously described (Nandi et al., 2008) and used between
passages 3 and 7 for all experiments. Human modified oxi-
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dized lipoprotein (RP-048 – Source BioScience Life Sciences,
Nottingham, UK) (100 μg·mL−1) (Feldmann et al., 2013) was
incubated with cells for 2 h to induce oxidative stress (Bowers
et al., 2011). L-Phe (500 μM; 0.5 h) or vehicle control was
subsequently added to cells, and the impact on nitrite accu-
mulation (a correlate of nitric oxide) in the media and BH4 in
cell lysates was assessed.
BH4 measurement. Biopterin and BH4 were measured in cell
lysates, tissue and plasma, as previously described using fluo-
rescence and electrochemical detection following sample
separation by HPLC (Howells et al., 1986; Starr et al., 2014).
Quantification was performed by comparison with external
standards after normalizing for sample protein content. All
analyses were conducted in a blinded fashion and investiga-
tors were unblinded to treatment/genotype following com-
pletion of data analysis.
Nitrite measurement. Plasma or tissue homogenates were
deproteinated and nitrite content was then quantified using a
fluorometric method utilizing 2,3-diaminonaphthalene
(Bryan and Grisham, 2007). The amount of nitrite in each
sample, expressed as micromolar nitrite·per milligram
protein was calculated from a linear calibration curve of
known nitrite concentrations (linear range: 0.5–5 μM) and
normalized for total amount of protein.
Chemiluminescent measurement of superoxide anion. Superox-
ide levels were quantified from sEnd1 cells using a Lucigenin
chemiluminescence-based assay (Li and Shah, 2001). Briefly,
cells were seeded at equal density in a 96-well microplate
luminometer (Model Lucy 1, Rosys Anthos, Austria) and pre-
treated with human modified oxidized lipoprotein ± L-phe as
described above. Media were removed and replaced by 100 μL
Krebs solution (119 mM NaCl, 4.7 mM KCl, 1.5 mM MgSO4,
2.5 mM CaCl2, 25 mM NaHCO3, 1.2 mM KH2PO4, 11 mM
glucose and 100 μM L-arginine), pH 7.4, and were kept cold
on ice. Immediately before recording chemiluminescence,
NADPH (final concentration 100 μmol·L−1) and lucigenin, bis-
N-methylacridinium nitrate (10 μmol·L−1) was added to
tissues and superoxide dismutase (SOD, 200 units·mL−1) was
used as a positive control. Light emission was recorded as
mean arbitrary light units/cycle over 60 min.
Data analysis
SPR data were analysed using the curve fitting software Origin
7.0 (OriginLab Corporation, Northampton, MA, USA) and
Biaevaluation software to determine the kon and koff rate con-
stants and binding parameters, using both first and second
order kinetic models. Bmax calculations were normalized for
surface density when this differed between experiments. A
global fitting approach using the Biaevaluation software was
not adequate to fully describe and fit the binding curves.
Therefore, individual curve fitting was conducted in order to
calculate binding parameters and rate constants (Supporting
Information Fig. S2). The representative data shown in the
results (Figure 2) were best described using first-order kinetics;
hence the values were determined using monophasic fits.
For HPLC based assays, data are presented as mean ± SEM
(where n = number of animals). One-way analysis of variance
was used to analyse data obtained from HPLC-based assays
measuring BH4, biopterin, nitrite and superoxide anion levels
in vascular tissues, plasma, cells and media. For the real-time
kinetic assays, data are presented as mean ± SEM (where n =
number of cell pellets from individually grown cultures).
Two-way analysis of variance was used to analyse activity data
from kinetic assays. GraphPad Prism 5 (GraphPad Software
Inc, La Jolla, CA, USA) was employed to analyse all assay data.
Materials
Bacterial culture reagents, plasmid vectors and competent
cells were purchased from Novagen, VWR International. Oli-
gonucleotide primers were synthesized by Sigma-Aldrich
(Dorset, UK). All other reagents were purchased from Sigma-
Aldrich unless otherwise stated.
Results
Expression and activity of native/full length
and T-GCH1 with GFRP
Soluble human recombinant T-GCH1, F-GCH1 and GFRP
proteins were successfully expressed individually in BL21
(GCH1) or Rosetta (GFRP) cells (Figure 1A). In dual expression
cultures, metal affinity purification of His6T-GCH1 or His6F-
GCH1 revealed that GFRP was able to bind to both forms of
GCH1 and could be co-isolated (Figure 1B).
Western blotting using specific antibodies revealed immu-
noreactive bands for GFRP and all His-tagged proteins
(Figure 1C, i and ii). The GCH1 antibody (which recognizes an
N-terminal epitope) correctly identified native but not
T-GCH1 (Figure 1C, iii), confirming an intact N-terminal
region on native GCH1 and demonstrating that the two forms
of GCH1 could be readily distinguished from one another.
Activity assays and native PAGE gels run immediately
before SPR analysis, demonstrating that proteins were pre-
dominantly in an oligomeric form (Figure 1D–F) (Maita et al.,
2001). Consistent with previous reports (Higgins and Gross,
2011), F-GCH1 displayed lower levels of activity compared
with T-GCH1 (Figure 1E), an effect that was reversed when
F-GCH1 was co-incubated with GFRP (Figure 1F)
Protein–protein interactions between native or
T-GCH1 with GFRP
Representative binding profiles illustrate differences between
GFRP binding to F-GCH1 (Figure 2A, left) or T-GCH1
(Figure 2A, right). Binding parameters and determined kon and
koff values are listed in the associated table. Binding was observed
between both forms of GCH1 with GFRP, in the absence of
additional L-phe, BH4 or GTP. The analysis yielded KD values of
8 nM for F-GCH1 : GFRP and 17 nM for T-GCH1 : GFRP in the
absence of ligands (tabulated in Figure 2A).
Effects of L-phe on F-GCH1–GFRP
protein–protein interactions
L-phe changed both the association and dissociation rate
constants with both forms of GCH1 and GFRP resulting in an
eight-fold increase in binding affinity for F-GCH1–GFRP
interactions: 1 nM KD, and 10-fold increase in binding affinity
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Figure 1
Expression and activity of human recombinant native/full length GCH1 (F-GCH1), truncated GCH1 (T-GCH1) and GTP cyclohydrolase 1 (GCH1)
feedback regulatory protein (GFRP). (A) F-GCH1 expression in uninduced (lane 1) and IPTG induced (lane 2) cells. T-GCH1 expression from IPTG
induced (lanes 3 and 4) cells. GFRP expression in uninduced (lane 5) and IPTG (isopropyl β-D-1-thiogalactopyranoside) induced (lanes 6 and 7)
cells. Products were resolved on a 4–15% SDS-PAGE gradient gel. (B) Elution of purified proteins from dual expression cultures: His-T-GCH1 and
GFRP bands are observed at ∼25 and ∼10 kDa, respectively; His-F-GCH1–GFRP bands observed at ∼28 and ∼10 kDa respectively. (C) (i):
Immunoreactive bands for GFRP at ∼10 kDa were observed using a commercially available GFRP antibody; (ii) immunoreactive bands for both
GFRP and T-GCH1 using a commercially available His-tag antibody were observed at ∼10 and ∼24 kDa, respectively; (iii) immunoreactive band
at ∼28 kDa for F-GCH1 using an N-terminal GCH1 antibody; no immunoreactive bands for T-GCH1. (D) Native 5% PAGE gels run prior to surface
plasmon resonance (SPR) analysis. Predominant bands highlighted for F-GCH1, T-GCH1 and GFRP as indicated, from two independent
experiments. (E) Activity of purified F-GCH1 and T-GCH1 was quantified by HPLC detecting neopterin production; mouse liver homogenate and
empty vector control were used for comparison (n = 6, mean ± SEM). *P < 0.05, ***P < 0.001, significantly different from control. (F) GCH1 activity
measured by microplate assay in the presence of 250 nM GCH1, 1 μM GFRP and 100 μM GTP (n = 10, mean ± SEM). ***P < 0.01, significantly
different from F-GCH1 without GFRP).
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Figure 2
Surface plasmon resonance sensorgrams and tabulated data for His-tag captured native/full length GCH1 (F-GCH1) or truncated GCH1 (T-GCH1)
interacting with GCH1 feedback regulatory protein (GFRP) analyte in the absence and presence of L-phenylalanin (L-phe). (A) Representative
sensorgrams comparing F-GCH1–GFRP binding curves (left) and T-GCH1–GFRP binding curves (right). GTP-cyclohydrolase 1 (GCH1) is captured
at a surface density of ∼1300 RU via His-capture, and GFRP is introduced in varying concentrations (12.5–400 nM) with tabulated first-order
dissociation constants (KD) and on- and off-rate constants (n = 4). (B) Representative sensorgrams for GFRP binding to F-GCH1 in the presence
of L-phe. GCH1 immobilized at a surface density of ∼1500 RU via His-capture, and GFRP and L-phe are introduced in varying concentrations
(12.5–400 nM), with tabulated first-order dissociation constants (KD) and on- and off-rate constants are tabulated (n = 4). (C) Comparison of
binding kinetics; binding profiles for T-GCH1 and F-GCH1 in the presence and absence of ligands with 400 nM GFRP; F-GCH1 + GFRP; T-GCH1
+ GFRP; F-GCH1 + GFRP + L-phe.
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for T-GCH1–GFRP interactions: 1.7 nM KD. Representative
sensorgrams for F-GCH1–GFRP + L-Phe (Figure 2B); T-GCH1–
GFRP + L-Phe (Supporting Information Fig. S1) and corre-
sponding values for F-GCH1 and T-GCH1 are summarized in
the associated table (Figure 2B). In addition to these findings,
a clear, two-fold rise in maximal binding (Bmax) was observed
in F-GCH1–GFRP interactions in the presence of L-phe. A
comparison of SPR derived data and binding kinetics are
summarized in Figure 2C
The effect of BH4 (20 μM) on GCH1–GFRP interactions
was also investigated, revealing increased binding affinity in
its presence but no distinguishable differences between
T-GCH1–GFRP and F-GCH1–GFRP interactions (Supporting
Information Table S1).
Effects of L-phe challenge on Ox-LDL
pre-treated endothelial cells
Addition of human modified oxidized lipoprotein to
endothelial cells led to a significant elevation of superoxide
anion (Figure 3A), reduction in nitrite (Figure 3B) and reduc-
tion in BH4 (Figure 3C) compared to baseline and consistent
with published observations (Bowers et al., 2011). Applica-
tion of L-phe (500 μM, 30 min) restored superoxide, nitrite
and BH4 towards baseline levels (Figure 3A–C).
Effects of oral L-phe challenge on biopterin
and BH4 levels in vivo
Oral L-phe challenge (100 mg·kg−1 bolus) in C57BL/6 mice led
to a peak plasma L-phe concentration at 20 min which nor-
malized to baseline by 4 h (Figure 4A). Similarly, the peak
increase in plasma biopterin was rapid and normalized by 8 h
(Figure 4B). In contrast, biopterin in aortic tissue followed a
different profile, showing a more gradual and continual rise
over the 8 h period (Figure 4C). Importantly, the functionally
important pterin, BH4 (which behaves as an NOS cofactor and
has vaso-protective properties), was also significantly elevated
in aorta 4 h after administration of L-phe, normalizing by 8 h
(Figure 4D). Finally, whilst administration of L-phe to GCH1
wild-type littermates stimulated biopterin/BH4 production in
a similar manner to that observed in commercially purchased
C57BL/6 mice (Figure 4B, E and F), L-phe had no significant
effect in mice lacking endothelial GCH1 [GCH1(fl/fl)-Tie2Cre]
(Figure 4E and F). These data suggest that L-phe stimulates
endothelial GCH1, leading to a rise in BH4 in the aorta.
Discussion and conclusion
Protein interactions of native and truncated
GCH1 with GFRP
Published structural studies of the GCH1–GFRP complex
have used a truncated form of mammalian GCH1, lacking a
large portion of the N-terminal region, suggesting that this
region had no influence on either activity or binding to GFRP
(Auerbach et al., 2000; Maita et al., 2002; 2004). This sugges-
tion has, however, been challenged, as the N-terminal region
has been shown to modulate GCH1 activity and to be essen-
tial for GFRP binding (Swick and Kapatos, 2006; Higgins and
Gross, 2011). Furthermore, previous studies have suggested
that the known ligands, L-phe and BH4, or substrate, GTP, are
an essential requirement for GCH1–GFRP binding (Harada
et al., 1993; Yoneyama and Hatakeyama, 1998).
In contrast to these observations, using SPR, we have
shown that T-GCH1 and F-GCH1 are able to bind to GFRP
with nanomolar affinity, in the absence of known ligands and
substrate. Furthermore, whilst the N-terminal region mod-
estly enhanced the affinity of interaction with GFRP, high
Figure 3
Effects of L-phenylalanine (L-phe) challenge on superoxide anion,
nitrite and 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) levels in
cultured endothelial (sEnd1) cells in the presence and absence of
human modified oxidized lipoprotein. (A) Cellular superoxide anion
concentration as quantified by mean arbitrary lights units (lucigenin
chemiluminescence) using superoxide dismutase as positive control,
(B) nitrite accumulation in media, (C) cellular BH4 concentration, in
sEnd 1 cells untreated (UT) or treated with Human modified oxidized
lipoprotein (100 μM, 2 h) in the absence or presence of L-phe
(500 μM, 0.5 h); n = 4–9, mean ± SEM. *P < 0.05, significantly
different from untreated control).
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affinity interactions were still observed between T-GCH1 and
GFRP. This ability of both native and truncated forms of
GCH1 to interact with GFRP was independently confirmed
using a GCH1–GFRP dual expression plasmid, where
untagged GFRP was co-isolated with both His6-F-GCH1 and
His6-T-GCH1. These findings are inconsistent with yeast
two hybrid studies, in which N-terminal deletion diminished
GCH1–GFRP interactions by 80% (Swick and Kapatos,
2006) or where the truncated enzyme displayed a relative
inability to engage in higher ordered complexes with His6-
GFRP (Higgins and Gross, 2011). The reasons for this discrep-
ancy probably reflect differences in protein expression
methodologies and the enhanced sensitivity of SPR to detect
protein–protein interactions. A noticeable difference in
maximal binding (Bmax) between F-GCH1–GFRP and TGCH1–
GFRP was, however, detected, suggesting altered stoichiom-
etry between the native and truncated complexes – a finding
that requires further investigation but beyond the scope of
the current study. Furthermore, absence of the N-terminal
region conferred higher measured activity consistent with
published observations (Higgins and Gross, 2011). It has been
suggested that the N-terminal region may exert an auto-
inhibitory effect leading to the observed activity changes
mediated via a direct peptide bond, rather than a transient
obstruction of the active site by a mobile N-terminal region
(Higgins and Gross, 2011). Furthermore, instability of the
full-length enzyme during purification has been reported by
several groups (Yim and Brown, 1976; Auerbach et al., 2000),
and it may equally be feasible that the enhanced activity of
T-GCH1 can be, in part, attributed to greater T-GCH1 stability
compared to F-GCH1 following purification. Together, our
in vitro and biophysical data indicate that the GCH1
N-terminal region is not essential for GFRP binding, but that
GCH1–GFRP binding kinetics and activity are altered when
the N-terminal region is deleted – indicating a functionally
important role for this region.
Figure 4
Effects of oral L-phe challenge on systemic and vascular biopterin levels in wild-type mice and GCH1(fl/fl)-Tie2Cre (KO) mice. (A) Plasma
L-phenylalanine, (B) plasma total biopterins, (C) aortic total biopterins and (D) aortic 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) levels
detected by HPLC, over an 8 h time course, following 100 mg·kg−1 oral L-phe challenge in wild-type mice. n = 6–12 for plasma and n = 4–8 aorta,
mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05: significantly different from saline control. (E) Aortic total biopterins and (F) aortic BH4 levels in
GCH1(fl/fl)-Tie2Cre (KO) mice and wild-type littermates, 1 and 4 h after 100 mg·kg−1 oral L-phe challenge. n = 6–8, mean ± SEM. **P < 0.01,
significantly different from WT saline.
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Effects of L-phe on GCH1–GFRP interactions
The interactions between GFRP and both forms of GCH1
were subsequently quantified in the presence of the allosteric
effector molecule, L-phe. Whilst both forms of GCH1 were
able to bind to GFRP in its absence, L-phe changed both the
association and dissociation rate constants between both
forms of GCH1 and GFRP, resulting in an 8- to 10-fold
increase in binding affinity – an effect that was mimicked by
another allosteric modulator, BH4. The increase in binding
affinity induced by L-phe between the truncated and native
forms of GCH1 with GFRP was indistinguishable. These
changes in binding affinity are consistent with the structural
changes reported in the stimulatory crystal structure of the
rodent T-GCH1–GFRP complex (Maita et al., 2002).
For the physiologically expressed form (F-GCH1) a clear
two-fold rise in maximal binding (Bmax) values was also
observed upon the addition of L-phe, indicating a different
stoichiometry to that previously suggested (Maita et al.,
2002). This unexpected observation is, however, consistent
with a previous report that native GCH1 binding to GFRP
generates a very high molecular weight band which exceeds
the size that would have been predicted for a GCH1 homo-
decamer bound to a GFRP pentamer (Higgins and Gross,
2011). However, further studies are required to fully under-
stand this observation.
We thus demonstrate that SPR can readily detect the
changes in GCH1–GFRP protein interactions, induced by
small effector molecules such as L-phe. The very slow disso-
ciation rates between GCH1 and GFRP observed using SPR
indicate that within a physiological context, the two proteins
would likely remain tightly complexed to one another.
L-phe challenge on BH4, nitric oxide and
superoxide anion levels in vitro
We used an in vitro model of endothelial dysfunction and
eNOS ‘uncoupling’ (Xie et al., 2012) to establish the effects of
L-phe on BH4 and nitrite levels. Consistent with previous
reports, incubation of endothelial cells with human oxidized
lipoprotein led to a significant elevation of superoxide anion
levels and concomitant reduction in nitrite and BH4. Incuba-
tion with L-phe reversed this effect, indicating that stimula-
tion of endothelial GCH1 by L-phe analogues has the
potential to reverse endothelial dysfunction.
L-phe challenge on biopterin and BH4 levels
in vivo
A single 100 mg·kg−1 L-phe oral dose led to a significant
increase in plasma and aortic biopterin/BH4 levels, in all
wild-type mice – an effect that was not observed in aortas
from GCH1(fl/fl)-Tie2Cre mice. Based on published evidence
and data obtained in this study, we conclude that the raised
biopterin/BH4 levels following oral L-phe administration
occur via activation of the GCH1 : GFRP complex in endothe-
lial cells (Harada et al., 1993; Saunders-Pullman et al., 2004).
Interestingly, aortic BH4 was still detectable in mice
lacking endothelial GCH1, suggesting that cell types such as
smooth muscle or adventitial fibroblasts may also generate
BH4. Our findings are in agreement with the initial charac-
terization of these genetically modified mice, which demon-
strated that endothelial GCH1 gene deletion or endothelial
denudation in wild-type mice reduced, but did not abolish,
aortic BH4 levels (Chuaiphichai et al., 2014). Whilst we were
unable to show a statistically significant difference in basal
BH4 levels within aortic tissue between GCH1(fl/fl)-Tie2Cre
mice and WT littermates, we did observe a trend reduction in
the baseline state – the differences observed between this
study and that of Chuaiphichai et al. (2014) are likely to
reflect subtle differences in tissue dissection and preparation.
Importantly, in the present study, L-phe administration
did not stimulate a significant rise in aortic BH4 in GCH1(fl/
fl)-Tie2Cre mice, indicating that the GCH1–GFRP complex is
primarily located in endothelial cells. As such, novel thera-
pies activating the GCH1–GFRP axis are most likely to target
this cell type. Indeed, the vascular endothelium is believed to
be the primary source of BH4 (d’Uscio and Katusic, 2006), and
previous studies have demonstrated that changes in GCH1–
GFRP interactions are a critical regulator of BH4 and NO
biosynthesis in endothelial cells, in response to laminar shear
stress (Li et al., 2010).
The profiles of plasma L-phe and biopterin in mice mir-
rored that previously observed in humans challenged with
oral L-phe (Saunders-Pullman et al., 2004), indicating that
this is a suitable and clinically translatable model with which
to investigate the GCH1–GFRP axis.
The observation that L-phe challenge stimulated aortic
BH4 levels for at least 4 h is encouraging, as it suggests that
the activation of the GCH1–GFRP complex elicits a sustained
elevation of vaso-protective BH4 in target vascular tissues.
These in vitro and in vivo findings thus provide mechanistic
evidence to support published functional studies that have
shown that L-phe administration restores endothelial
function and attenuates the observed hypertension induced
by administration of the GCH1 inhibitor di-amino-
hydroxypyrimidine (Mitchell et al., 2004).
In conclusion, we have undertaken a detailed analysis of
GCH1 and GFRP using complementary in vitro biophysical
analysis with in vitro and in vivo murine studies. We have
successfully expressed soluble human GCH1 and GFRP and,
for the first time, quantified the binding rate constants
between GCH1 and GFRP, using SPR. We have also demon-
strated that the N-terminal region of GCH1 is not essential
for GFRP to interact, but that deletion of this region alters the
binding kinetics between the two proteins. Whilst GCH1 and
GFRP were able to bind in the absence of known ligands, the
presence of L-phe substantially elevated the maximal binding
and the affinity of interaction – suggesting that, in an in vivo
system (where ligands and substrate would be circulating),
the two proteins would display high affinity interactions.
Indeed, the rapid rise in plasma biopterin (observed within
20 min) coupled with slow GCH1–GFRP dissociation rates
(obtained by SPR) supports the view that GCH1 and GFRP are
likely to be constitutively bound in vivo, rather than binding
in response to an acute elevation of circulating L-phe, follow-
ing dietary intake.
Our biophysical and in vivo data suggest that the L-phe
binding pockets on the GCH1–GFRP complex represent a
rational drug target to raise vascular BH4, for the treatment of
endothelial dysfunction. It is important to note that L-phe
itself is not a feasible chronic therapeutic intervention due to
its diverse physiological functions and role in catecholamine
biosynthesis. However, given the marked allosteric changes
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induced by L-phe, low MW small molecule mimetics that
alter interactions between GCH1 and GFRP in a similar
manner have the potential to regulate intracellular BH4 for
therapeutic purposes. Indeed, the sustained effect on aortic
BH4 levels following a single oral L-phe challenge is highly
encouraging from a therapeutic standpoint as this could
elevate endothelial NO levels and/or limit damaging reactive
oxygen species, circumventing the limited bioavailability/
efficacy of oral BH4. Such an agent would have use in a wide
spectrum of cardiovascular diseases, underpinned by reduced
NO bioavailability and/or enhanced oxidative stress.
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Figure S1 Binding profile for truncated GCH1 (T-GCH1)
with GCH1 feedback regulatory protein (GFRP) in the pres-
ence of L-phenylalanine (L-phe). T-GCH1 is immobilized at a
surface density of ∼1500 RU via His-capture, and GFRP and
L-phe are introduced in varying concentrations (400–25 nM)
(n = 4 for each experiment at varying immobilization
patterns and surface densities). Representative sensorgrams
are shown.
Figure S2 SPR data analysis by Origin software, curve fittings
and residuals.
Table S1 Summary of the binding kinetics for both native/
full-length GCH1 (F-GCH1) and GCH1 feedback regulatory
protein (GFRP) as well as truncated GCH1 (T-GCH1) and
GFRP in the presence and absence of BH.
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